Submitted by web@researchtop... on Fri, 07/19/2013 - 11:52
Crizotinib in advanced NSCLC harboring ROS1 gene rearrangement (Abstract)
Key Points
- Phase I study (N = 15) of crizotinib in ROS1-rearranged advanced NSCLC
- ORR 57% and stable disease rate 29%, validating ROS1 as a therapeutic target
- AEs primarily Grade 1, including visual impairment, AST increase, peripheral edema, nausea and diarrhea
Dr Love’s Take
ROS1 rearrangements are even less common than ALK translocations, but the results of this initial experience suggest a similar response pattern in that 8 of 14 evaluable patients experienced objective tumor responses to crizotinib. This has effectively identified ROS1 as the third mutation in NSCLC that is currently targetable, and it provides the impetus for more widespread FISH testing, particularly for nonsmokers without EGFR mutations or ALK translocations.
